首页> 外国专利> DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A NEUROTROPHIC AGENT, A C-TYPE NATRIURETIC PEPTIDE, A NATRIURETIC PEPTIDE RECEPTOR-B, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR OR A FAS-LIGAND INHIBITOR FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION

DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A NEUROTROPHIC AGENT, A C-TYPE NATRIURETIC PEPTIDE, A NATRIURETIC PEPTIDE RECEPTOR-B, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR OR A FAS-LIGAND INHIBITOR FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION

机译:药物输送系统,包括眼内压降剂,神经营养剂,C型利尿肽,B型利尿肽受体,凋亡信号抑制因子抑制剂或治疗点的Fas-library抑制剂。

摘要

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.
机译:本公开涉及一种药物递送系统,其包含眼内降压剂,神经营养剂,例如CNTF化合物,C型利钠肽(CNP)化合物,Tie-2激动剂,利钠肽受体-B(NPR)。 -B)化合物或凋亡信号片段抑制剂(FAS)或FAS-配体(FASL)抑制剂,包括这些化合物和持续递送成分的任意组合。还描述了治疗青光眼或相关病症的方法,药物,试剂盒,用途和制造方法。

著录项

  • 公开/公告号US2020108117A1

    专利类型

  • 公开/公告日2020-04-09

    原文格式PDF

  • 申请/专利权人 CELLA THERAPEUTICS LLC;

    申请/专利号US201916719703

  • 发明设计人 RHETT M. SCHIFFMAN;LUKAS SCHEIBLER;

    申请日2019-12-18

  • 分类号A61K38/08;A61K38/07;A61K31/192;A61P27/06;

  • 国家 US

  • 入库时间 2022-08-21 11:19:31

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号